TITLE

Repetitive Transcranial Magnetic Stimulation: Does it Have Potential in the Treatment of Depression?

AUTHOR(S)
Padberg, Frank; Möller, Hans-Jürgen
PUB. DATE
April 2003
SOURCE
CNS Drugs;2003, Vol. 17 Issue 6, p383
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Transcranial magnetic stimulation (TMS) has become a major research tool in experimental clinical neurophysiology as a result of its potential to noninvasively and focally stimulate cortical brain regions. Currently, studies are being conducted to investigate whether repetitive TMS (rTMS)-mediated modulation of cortical function may also provide a therapeutic approach in neurological and psychiatric disorders. Preclinical findings have shown that prefrontal rTMS can modulate the function of fronto-limbic circuits, which is reversibly altered in major depression. rTMS has also been found to exert effects on neurotransmitter systems involved in the pathophysiology of major depression (e.g. stimulates subcortical dopamine release and acts on the hypothalamic pituitary adrenal axis, which is dysregulated in depression). To date, numerous open and controlled clinical trials with widely differing stimulation parameters have explored the antidepressant potential of rTMS. Though conducted with small sample sizes, the majority of the controlled trials demonstrated significant antidepressant effects of active rTMS compared with a sham condition. Effect sizes, however, varied from modest to substantial, and the patient selection focused on therapy-resistant cases. Moreover, the average treatment duration was approximately 2 weeks, which is short compared with other antidepressant interventions. Larger multicentre trials, which would be mandatory to demonstrate the antidepressant effectiveness of rTMS, have not been conducted to date. A putative future application of rTMS may be the treatment of patients who did not tolerate or did not respond to antidepressant pharmacotherapy before trying more invasive strategies such as electroconvulsive therapy and vagus nerve stimulation. Theoretically, rTMS may be also applied early in the course of disease in order to speed up and increase the effects of antidepressant pharmacotherapy. However, this application has not been a focus of clinical trials to date. Research efforts should be intensified to further investigate the effectiveness of rTMS as an antidepressant intervention and to test specific applications of the technique in the treatment of depressive episodes.
ACCESSION #
9633640

 

Related Articles

  • Managing depression: an overview.  // Mental Health Practice;Jun2004, Vol. 7 Issue 9, p33 

    Presents an overview on how to manage depression. Definition of depression; Symptoms of depression; Severity and duration; Causes; Treatment and prevention; Developments in antidepressant medication.

  • Depression: How Medicine Can Help.  // American Family Physician;3/1/2000, Vol. 61 Issue 5, special section p1 

    Reveals how medicine can help depression, a mental illness like diabetes or high blood pressure. Causes of depression; Treatment for depression; Things considered by doctor before choosing antidepressant medicine for depressed persons; Different kinds of antidepressants.

  • Toxoplasma seropositivity and depression: a case report. Kar, Nilamadhab; Misra, Baikunthanath // BMC Psychiatry;2004, Vol. 4, p1 

    Background: The association between toxoplasmosis and psychiatric disorders has been reported in a few anecdotal reports. Case Presentation: A case of depression with toxoplasma seropositivity is presented. The patient with depression showed poor response to antidepressants, for which he was...

  • No malformation risk of SSRIs in pregnancy. Liddle, Rachel // GP: General Practitioner;7/6/2007, p8 

    The article reports on the results of a study which found that there is no evidence that the use of selective serotonin reuptake inhibitor (SSRI) to treat depression in pregnancy could create a risk of birth malformations. Researchers accounted that the risk of having affected child would be...

  • Taming the beast. Carter, Betty Smartt // Christian Century;8/09/2003, Vol. 120 Issue 16, p21 

    Focuses on the spiritual aspect of the use of antidepressants. Effectiveness of Saint John's Wort antidepressant herbal supplement; Factors that contribute to experiencing sadness; Information on laughter as a natural antidepressant; Moral and spiritual problems that arise from the physical...

  • Editorial [Hot Topic: Recent Strategies for Potentiation and Facilitation of Antidepressant Treatment (Guest Editor: Eliyahu Dremencov)]. Dremencov, Eliyahu // Current Drug Targets;Feb2006, Vol. 7 Issue 2, p135 

    It was my great honor and pleasure to be suggested for the guest editing of the theme issue in Current Drug Targets and to prepare this issue entitled "Recent strategies for potentiation and facilitation of antidepressant treatment". Major depression is a severe and dangerous mental disorder...

  • The duty to be Well-informed: The case of depression. Blease, Charlotte // Journal of Medical Ethics;Apr2014, Vol. 40 Issue 4, p225 

    It is now an ethical dictum that patients should be informed by physicians about their diagnosis, prognosis and treatment options. In this paper, I ask: 'How informed are the 'informers' in clinical practice?' Physicians have a duty to be 'well-informed': patient well-being depends not just in...

  • Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Tansey, K E; Rucker, J J H; Kavanagh, D H; Guipponi, M; Perroud, N; Bondolfi, G; Domenici, E; Evans, D M; Hauser, J; Henigsberg, N; Jerman, B; Maier, W; Mors, O; O'Donovan, M; Peters, T J; Placentino, A; Rietschel, M; Souery, D; Aitchison, K J; Craig, I // Pharmacogenomics Journal;Aug2014, Vol. 14 Issue 4, p395 

    It would be beneficial to find genetic predictors of antidepressant response to help personalise treatment of major depressive disorder (MDD). Rare copy number variants (CNVs) have been implicated in several psychiatric disorders, including MDD, but their role in antidepressant response has yet...

  • Nortriptyline.  // AHFS Consumer Medication Information;Jun2020, p1 

    Nortriptyline is used to treat depression. Nortriptyline is in a group of medications called tricyclic antidepressants. It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics